Skip to main content
. Author manuscript; available in PMC: 2011 May 26.
Published in final edited form as: Aliment Pharmacol Ther. 2009 Mar 26;30(1):14–27. doi: 10.1111/j.1365-2036.2009.04004.x

Table 2.

Three studies which assessed but do not separately report missed doses of interferon and ribavirin

Study No. of
subjects		 % HIV-co
-infected		 Type of study
/HCV treatment		 Method of adherence
assessment		 80/80/80 Adherence Adherence - virological
outcome relationship
McHutchison
 et al. 200228 		1521 0 3 clinical trials combined
 – interferon or
 PEG-IFN + RBV		 Pill counts (RBV) and
 subject diaries		 62% took at least 80% of prescribed
 interferon and at least 80% of prescribed
 ribavirin for at least 80% of the
 recommended duration of treatment
 and were considered ‘adherent’		 80/80/80 adherence was
 associated with SVR in
 genotype 1 but not
 genotype 2/3 subjects
Sola et al. 200629 157 50.3 Prospective-interferon
 + RBV		 Pill counts (RBV) and
 self-report questionnaire		 76% took at least 80% of prescribed
 interferon and at least 80% of prescribed
 ribavirin for at least 80% of the
 recommended duration of treatment and
 were considered ‘adherent’		 80/80/80 adherence was
 associated with SVR
Sylvestre and
 Clements 200727 		71 1.4 Prospective-interferon
 + RBV		 Return of empty vials (IFN);
 pill counts (RBV);
 self-report questionnaire		 68% took at least 80% of prescribed
 interferon and at least 80% of prescribed
 ribavirin for at least 80% of the
 recommended duration of treatment and
 were considered ‘adherent’		 80/80/80 adherence was
 associated with SVR